Natural Alternatives International and CarnoSyn Brands announced that TriBsyn supplementation significantly improves the bioavailability and efficiency of beta-alanine.
Also, it eliminates paresthesia, a common side effect that often discourages adherence to beta-alanine supplementation, which is crucial for muscle maintenance and cognitive health.
The announcement is based on a study published in Food Hydrocolloids for Health journal.
TriBsyn is an encapsulated beta-alanine complex that leverages CarnoSyn beta-alanine and Hydro Oleo technology to deliver higher bioavailability and potency.
Its patent-pending formulation facilitates effective dosages at lower volumes, ensuring superior delivery at both cellular and systemic levels.
The advanced absorption pathways include direct cellular uptake and traditional gastrointestinal routes.
Natural Alternatives International president and COO Ken Wolf said: “The TriBsyn clinical trial results clearly showed the elimination of paresthesia and an increased pharmacokinetic efficiency, confirming enhanced delivery and exceptional bioavailability.
“With its advanced Hydro Oleo technology and carnosine-boosting effects, TriBsyn provides scientifically proven claims to improve muscle vitality, muscle working capacity, and cognitive performance.
“It truly sets a new standard in beta-alanine supplementation and helps fill the gap for healthy ageing and wellness solutions, especially for the active ageing population, GLP-1 users, and those with plant-based diets.”
The study evaluated TriBsyn in a randomised, double-blind, single-dose, three-treatment, three-way crossover oral bioavailability study, in healthy older adults.
In the study, a low dose of TriBsyn 400mg was compared with a high dose of 1200mg doses of conventional beta-alanine under fasting conditions.
The results showed that TriBsyn 400 mg increased circulating beta-alanine plasma concentrations nearly 4.5 times and 1.3 times compared to 1200mg and 400mg of conventional beta-alanine, respectively.
In the study, sensory side effects were evaluated using the Visual Analogue Score (VAS) and Qualitative Light Symptoms Inventory (QLSI).
Also, no paresthesia or adverse effects were reported in the TriBsyn group, while conventional beta-alanine groups showed increasing paresthesia with dose.
TriBsyn recorded a VAS score of 0.62, indicating minimal symptoms, compared to scores of 2.02 and 4.01 for 400 mg and 1200 mg of conventional beta-alanine, respectively.
